Renaissance Capital’s Maravai LifeSciences MRVI Stock Holding History

Renaissance Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-55,443	Closed	-$554K	–	69
2023 Q3	$554K	Buy	55,443 +13,005	+31%	+$143K	0.29%	56
2023 Q2	$528K	Buy	42,438 +6,030	+17%	+$81.4K	0.3%	59
2023 Q1	$510K	Sell	36,408 -3,794	-9%	-$54.5K	0.38%	65
2022 Q4	$575K	Sell	40,202 -1,453	-3%	-$22.9K	0.45%	60
2022 Q3	$1.06M	Sell	41,655 -7,924	-16%	-$199K	0.68%	40
2022 Q2	$1.41M	Buy	49,579 +15,145	+44%	+$480K	0.75%	41
2022 Q1	$1.21M	Sell	34,434 -10,313	-23%	-$346K	0.52%	44
2021 Q4	$1.88M	Sell	44,747 -3,921	-8%	-$159K	0.48%	47
2021 Q3	$2.39M	Buy	+48,668	New	+$2.37M	0.48%	43

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Capital's MRVI Position: Q4 2023 in Review

Renaissance Capital sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 55,443 shares — an estimated $554K sold.

Renaissance Capital first reported a position in MRVI in Q3 2021 and held it in 9 quarters. The position peaked at $2.39M in Q3 2021. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

Renaissance Capital reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
Renaissance Capital sold 55,443 Maravai LifeSciences shares in Q4 2023, an estimated $554K.
Renaissance Capital first reported a position in Maravai LifeSciences in Q3 2021 and held it in 9 quarters.
Renaissance Capital's Maravai LifeSciences position peaked at $2.39M in Q3 2021.
223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on Renaissance Capital's 13F filing for Q4 2023, filed 5 Jan 2024.